Ascensia, Glooko improve diabetes management through new partnership

 

MOUNTAIN VIEW, Calif. — Ascensia Diabetes Care and Glooko on Tuesday announced a global technology partnership designed to bring together their diabetes management solutions and improve diabetes data management and analytics.



"Glooko's Diabetes Data Management Platform has become widely used for both personal and clinical diabetes data analytics and decision support," stated Michael Kloss, CEO of Ascensia Diabetes Care. "Glooko's broad distribution into health systems will enable us to easily and seamlessly deliver highly accurate data from our  Countour Next One and Contour Plus One blood glucose monitoring systems to clinicians right in their workflow," he said. "By linking our systems to Glooko's Diabetes Data Management Platform, we want to enable better understanding and analysis of diabetes data, and ultimately help to improve the lives of people with diabetes."



"The usability and accuracy of the Countour Next One and Contour Plus One blood glucose monitoring systems from Ascensia Diabetes Care is impressive and we are excited to bring this rich data into the Glooko platform to help both people with diabetes and their health care professionals manage this condition," added Rick Altinger, Glooko CEO.



The Countour Next One system recently received 510(k) clearance from the FDA and Ascensia Diabetes Care expects to make this system available in the United States in early 2017.



Glooko is a leading population health platform for diabetes management and enables people with diabetes to more easily track and better manage their condition using mobile, web and cloud technology. Glooko's mobile health app enables individuals to synchronize their data from a majority of the world's most popular diabetes and exercise devices including blood glucose meters. Glooko's population health application enables care teams to remotely support people with diabetes and aims to improve patient satisfaction and outcomes at a lower cost.



This global agreement covers all markets where Glooko and these Ascensia systems are available. The integration between these two solutions is expected to be available for people with diabetes and health care professionals later in 2017.